HCG.
Human chorionic gonadotropin (HCG) is a naturally occurring glycoprotein hormone produced by the placenta during pregnancy, and it is also manufactured as an FDA-approved injectable medicine.
Human chorionic gonadotropin (HCG) is a naturally occurring glycoprotein hormone produced by the placenta during pregnancy, and it is also manufactured as an FDA-approved injectable medicine. HCG is fda-approved, and PepCue grades its published evidence S tier (90/100). Also known as human chorionic gonadotropin · Pregnyl. This is a research reference, not medical or dosing advice.
What it is
Human chorionic gonadotropin (HCG) is a naturally occurring glycoprotein hormone produced by the placenta during pregnancy, and it is also manufactured as an FDA-approved injectable medicine. As a drug it is sold under brand names such as Pregnyl and Novarel (purified from urine) and Ovidrel (recombinant). It is used in reproductive and endocrine medicine rather than as a research peptide. Because its activity closely mimics luteinizing hormone (LH), it is used to stimulate the gonads in both males and females.
How it works
HCG shares strong structural similarity with LH and binds the LH/HCG receptor, effectively acting as an LH agonist. In males, this stimulates the Leydig cells of the testes to produce testosterone and can support spermatogenesis; in prepubertal boys with cryptorchidism it can promote testicular descent. In females undergoing fertility treatment, HCG triggers final oocyte maturation and ovulation after follicular development. These direct effects on the gonads are the basis for its approved clinical uses.
Mechanism pathways
Driving the pituitary and gonadal end of the reproductive hormone axis.
The reproductive axis runs in three stages. Gonadotropin-releasing hormone is secreted in pulses from the hypothalamus and acts on GnRH receptors on pituitary gonadotrope cells. Those cells release luteinizing hormone and follicle-stimulating hormone. LH and FSH then act on the gonads: in males LH drives Leydig cells to produce testosterone while FSH supports Sertoli cells and sperm production, and in females they govern follicular development, ovulation, and corpus luteum function. Sex steroids feed back on both the hypothalamus and pituitary to close the loop. The single most important feature of this pathway is that the pattern of stimulation determines the outcome, not just its presence. Brief, intermittent, pulsatile exposure to GnRH sustains LH and FSH release. Continuous exposure desensitises and downregulates the receptor, which after an initial surge shuts gonadotropin secretion down. This is why the same receptor is used both to switch the axis on, through pulsatile delivery, and to switch it off, through long-acting agonists used in prostate cancer, endometriosis, and precocious puberty. Anyone reasoning about a GnRH-targeting compound who ignores the delivery pattern will reach the wrong conclusion. Compounds here act at different levels. One is the natural decapeptide itself, engaging pituitary GnRH receptors directly. Another acts a step downstream: it is structurally similar to LH and binds the shared LH and chorionic gonadotropin receptor on gonadal cells, effectively substituting for LH and stimulating testosterone production or triggering final oocyte maturation depending on context. A third acts a step upstream, on the neurons that release GnRH in the first place. Because these compounds enter the axis at different points, they behave differently. Acting at the pituitary preserves gonadal feedback; acting directly on the gonad bypasses the pituitary entirely and does not require a functioning pituitary to work. Clinical grounding here is comparatively strong. Members of this group are approved medicines with defined indications in fertility medicine and endocrinology, and the physiology has been demonstrated in humans over decades. That established status applies to specific supervised medical uses. It does not extend to unsupervised use for hormone manipulation outside those indications, where dosing pattern errors can produce the opposite of the intended effect, and where suppression of the axis rather than stimulation is a real possibility.
The evidence
HCG has decades of established clinical use, and its FDA-approved indications are supported by its long regulatory and prescribing history rather than by a single pivotal trial. Approved uses include prepubertal cryptorchidism not due to anatomic obstruction, selected cases of hypogonadotropic hypogonadism in males, and induction of ovulation and pregnancy in carefully selected infertile women as part of assisted reproduction. In men, it is also used clinically to preserve testicular function and fertility, though some such uses are off-label. Much of this evidence base predates modern trial standards, so the supporting literature is a mixture of older controlled studies, registry and clinic series, and specialty guidance rather than large contemporary randomised trials with adjudicated endpoints. Notably, the FDA-approved labeling explicitly states there is no substantial evidence that HCG is effective for weight loss or fat redistribution, and it is not approved for weight loss. The weight-loss claim has actually been tested. A criteria-based meta-analysis published in the British Journal of Clinical Pharmacology in 1995 assessed controlled trials of HCG for obesity under the Simeons regimen and concluded that the evidence did not support an effect of HCG on weight loss, fat distribution, hunger or wellbeing. Where weight loss was observed in such programs, it is attributable to the severe caloric restriction that accompanied the injections rather than to the hormone. This contrasts sharply with actual obesity pharmacotherapy, where agents such as GLP-1 receptor agonists were approved on the basis of large randomised, double-blind, placebo-controlled Phase 3 trials with prespecified weight endpoints, and in some cases dedicated cardiovascular outcome trials. HCG has no comparable evidence for weight management. Its efficacy and safety for its endocrine and fertility indications are well characterized in the drug label and clinical guidelines.
The evidence, in brief
A placental glycoprotein hormone and an FDA-approved prescription injectable (Pregnyl, Novarel, Ovidrel) that acts as an LH analogue at the LH/HCG receptor. Its approved indications are endocrine and reproductive: prepubertal cryptorchidism, selected male hypogonadotropic hypogonadism, and ovulation induction in assisted reproduction. The FDA labeling states plainly that there is no substantial evidence HCG is effective for weight loss or fat redistribution, and over-the-counter HCG diet products are unapproved.
Evidence maturity
An evidence-only reading: approval status, human vs preclinical data, mechanism and safety. Popularity never raises it. Research file #027
Approved or strong, consistent human evidence.
FDA-approved for a specific indication: the strongest lane.
Claim receipts
Popular claims about HCG, checked against the state of the evidence. The verdict describes evidence maturity, never an invented study result.
The approved labeling states there is no substantial evidence for weight loss, and controlled trials pooled in a meta-analysis found no effect beyond the accompanying caloric restriction.
It binds the LH receptor and stimulates Leydig-cell testosterone production, which underpins its approved male endocrine indication.
Clinically used for this purpose with a substantial published record, though several such uses are off-label rather than approved indications.
Homeopathic and online HCG weight-loss products are unapproved, and injectable material outside a pharmacy has no verified potency, purity or sterility.
Recognized risks include ovarian hyperstimulation, multiple pregnancy and shifts in the testosterone to estradiol balance, which is why supervised use involves hormone testing and monitoring.
Safety profile
Recognized risks include ovarian hyperstimulation syndrome and increased chance of multiple pregnancy when used for ovulation induction, as well as injection-site reactions, headache, fatigue, mood changes, gynecomastia, and, rarely, arterial thromboembolism. HCG should not be used during pregnancy and requires medical supervision, particularly in patients with conditions sensitive to sex-steroid changes. Because HCG acts as an LH analogue, it raises endogenous sex-steroid production, so supervised use typically involves baseline and follow-up hormone testing, and in fertility settings ultrasound follicle monitoring and estradiol measurement precisely because ovarian hyperstimulation can escalate quickly and is occasionally severe. In males, prolonged stimulation can raise estradiol and affect the testosterone to estradiol balance, which is one reason clinical use is monitored rather than open-ended. Precocious puberty is a labelled concern when used in prepubertal boys. The labeling specifically warns against use for weight loss, including so-called 'HCG diet' regimens, which are not supported by evidence and may be paired with unsafe very-low-calorie dieting; the caloric restriction itself carries risks including nutrient deficiency, gallstones, electrolyte disturbance and loss of lean mass. A further hazard is supply. Over-the-counter, homeopathic and online HCG weight-loss products are unapproved, and injectable material obtained outside a pharmacy has no verified potency, purity or sterility, so unsupervised use adds an unregulated-product risk on top of a hormone that already needs clinical oversight.
Compound notes
- Human chorionic gonadotropin (HCG) is a naturally occurring placental glycoprotein hormone and also an FDA-approved prescription injectable; brands include Pregnyl and Novarel (urine-derived) and Ovidrel (recombinant).
- It closely resembles luteinizing hormone and binds the LH/HCG receptor, acting effectively as an LH agonist.
- In males it stimulates Leydig-cell testosterone production and can support spermatogenesis; in females it triggers final oocyte maturation and ovulation.
- Approved indications are prepubertal cryptorchidism not due to anatomic obstruction, selected male hypogonadotropic hypogonadism, and ovulation induction in assisted reproduction.
HCG acts downstream at the gonads as an LH mimic. Gonadorelin acts upstream at the pituitary as GnRH, prompting the body to release its own LH and FSH.
- The FDA-approved labeling states there is no substantial evidence that HCG is effective for weight loss or fat redistribution, and it is not approved for that use; over-the-counter homeopathic HCG weight-loss products are considered unapproved and illegal.
- Recognized risks include ovarian hyperstimulation syndrome and multiple pregnancy with ovulation induction, plus injection-site reactions, headache, fatigue, mood changes, gynecomastia, and rarely arterial thromboembolism.
- Prescription-only. It should not be used during pregnancy and requires medical supervision.
Regulatory status
HCG is FDA-approved as a prescription injectable for specified endocrine and fertility indications (e.g., Pregnyl, Novarel, Ovidrel). The FDA has stated that HCG is not approved and lacks substantial evidence for weight loss, and over-the-counter 'homeopathic' HCG weight-loss products are considered unapproved and illegal. It is a prescription-only medicine that requires clinical oversight.
Approved by the FDA for at least one indication.
By the numbers
- 01Placental glycoprotein hormone and an FDA-approved prescription injectable
- 02Acts as an LH analog at the LH/HCG receptor
- 03Stimulates testicular testosterone in males; triggers ovulation in females
- 04Approved for cryptorchidism, male hypogonadotropic hypogonadism, and ovulation induction
- 05Brands include Pregnyl, Novarel (urine-derived) and Ovidrel (recombinant)
- 06FDA: not approved and no substantial evidence for weight loss
HCG: research formats
Choose the format you are researching to see route-specific notes.
Pregnyl and Novarel are lyophilized powders reconstituted with the supplied diluent for IM injection.
HCG is a genuine FDA-approved prescription injectable, not a research peptide. The urine-derived products Pregnyl and Novarel are supplied as lyophilized powder with a bacteriostatic diluent and are labeled for intramuscular injection. The presentation below is a public labeling fact; the regimen itself depends on the indication and is set by the prescriber.
The labeled indications are cryptorchidism, male hypogonadotropic hypogonadism, and ovulation induction. Each carries its own regimen in the prescribing information, and this page does not reproduce them.
The FDA has stated that HCG is not approved and lacks substantial evidence for weight loss, and that over-the-counter 'homeopathic' HCG weight-loss products are unapproved and illegal.
Sources
Every factual claim above resolves to a real, published source.
- Chorionic gonadotropin (Pregnyl, Novarel) prescribing informationDailyMed (U.S. National Library of Medicine) drug label search
- Pregnyl (chorionic gonadotropin for injection) FDA labelFDA Drugs@FDA approved label, 2011
- The effect of human chorionic gonadotropin (HCG) in the treatment of obesity by means of the Simeons therapy: a criteria-based meta-analysisLijesen GK, et al. Br J Clin Pharmacol, 1995 · PMID 8527285
- Human chorionic gonadotropin and weight loss (PubMed search)PubMed search results
- Ovidrel (choriogonadotropin alfa) prescribing informationDailyMed (U.S. National Library of Medicine) drug label search
Cite this page
PepCue. “HCG: the evidence.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/p/hcg.
Log your doses, run the vial math, and keep a provider-ready record in PepCue.